Inflammatory breast cancer is a rare presentation of invasive breast cancer and has a poor prognosis. After a thorough workup, including imaging and a biopsy which demonstrates involved dermal lymphatics, the patient should begin neoadjuvant chemotherapy. Total mastectomy and axillary node dissection are the most likely course of surgical management. Patients who are either ER/PR or HER-2/neu positive may benefit from the addition of targeted therapy, although most inflammatory cancers are triple negative. Patients are at significant risk of recurrence and/or metastatic disease and should be followed closely.
Inflammatory Cancer Breast Dermal lymphatics Neoadjuvant Modified radical mastectomy
This is a preview of subscription content, log in to check access.
Dawood S, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22(3):515–23.CrossRefGoogle Scholar
van Uden DJ, et al. Inflammatory breast cancer: an overview. Crit Rev Oncol Hematol. 2015;93(2):116–26.CrossRefGoogle Scholar
Yamauchi H, et al. Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012;17(7):891–9.CrossRefGoogle Scholar
Network NCC. NCCN – evidence blocks – inflammatory breast cancer, in NCCN guidelines version 2.2016 – Invasive breast cancer. 2016. p. 1–2.Google Scholar
Cancer AJCO. Breast cancer staging. 8th ed: Chicago, Illinois: A. C. Society; 2017.Google Scholar
Wecsler JS, et al. Lymph node status in inflammatory breast cancer. Breast Cancer Res Treat. 2015;151(1):113–20.CrossRefGoogle Scholar